Global Statistics

spot_img

Conference Coverage

HaemaLogiX wins Most Promising CAR-T Pipeline in APAC

Australian biotech HaemaLogiX was awarded the Most Promising CAR-T Pipeline in APAC at the Asia Pacific CGT (Cell and Gene Therapy) Excellence Awards 2025,...

ASCO 2025: Satricabtagene Autoleucel Significantly Improves PFS and OS in advanced Gastric or Gastroesophageal Junction Carcinoma

Satricabtagene autoleucel (CT041; satri-cel; CARsgen Therapeutics), an autologous chimeric antigen receptor (CAR) T-cell product candidate against protein Claudin18.2, improves progression-free survival (PFS) and overall...

ESMO 2021: CT041, A New CAR-T for the Treatment of in Advanced Gastric Cancer

Each year, approximately one million new cases of gastric cancer, diseases of malignant glandular cells, are diagnosed worldwide. And despite recent advances in treatment...

Recent Articles

Stay on op - Ge the daily news in your inbox

spot_img